產(chǎn)品詳情
簡單介紹：
Anti-Six3抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-Six3抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-Six3
Cat. Number:
Anti-Six3抗體KL-11970R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The Six proteins (sine oculis) are a family of homeodomain transcription factors that share a conserved DNA binding domain. Six3 is required for the specification and proliferation of the eye field in vertebrates and may Anti-Six3抗體be involved in some developmental disorders of the brain. Expression of Six3 is detected in human embryos as early as five to seven weeks of gestation, and is maintained in the eye throughout the entire period of fetal development. At 20 weeks of gestation, expression of Six3 in the human retina has been observed in ganglion cells and in cells of the inner nuclear layer. Six3 maps to human chromosome 2p16-p21, between genetic markers D2S119 and D2S288. The map position of human Six3 overlaps the positions of two dominant disorders (holoprosencephaly type 2 and Malattia leventinese) with ocular phenotypes that have been assigned to this chromosomal region.
Also known as:
Homeobox protein SIX3; HPE2; Anti-Six3抗體Sine oculis homeobox homolog 3; SIX homeobox 3; Six3; SIX3_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, .
●
Immunogen: KLH conjugated Anti-Six3抗體synthetic peptide derived from human Six3.
●
Predicted Molecular Weight: 35kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-Six3抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
